Drug intelligence / Profile preview

AVM0703

Development stage: Phase 2
Lead developer: AVM Biotechnology
Modality: Small Molecules
Administration: Intravenous

Overview

AVM0703 is an immunomodulatory small molecule drug developed by AVM Biotechnology. It is designed to treat various types of lymphoma and leukemia by mobilizing immune cells such as natural killer T-cells, gamma delta T cells, and dendritic cells to target and destroy tumors. AVM0703 has shown potential in reducing the need for chemotherapy and is being explored for its ability to precondition patients for CAR-T cell therapy. It is currently in Phase 2 trials for relapsed/refractory Non-Hodgkin's Lymphoma.

Other names: Supra-pharmacologic dexamethasone sodium phosphate

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on AVM0703.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVM0703.

Explore the full profile